Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 11 |
NetGPI | no | yes: 0, no: 11 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005783 | endoplasmic reticulum | 5 | 1 |
GO:0043226 | organelle | 2 | 1 |
GO:0043227 | membrane-bounded organelle | 3 | 1 |
GO:0043229 | intracellular organelle | 3 | 1 |
GO:0043231 | intracellular membrane-bounded organelle | 4 | 1 |
GO:0110165 | cellular anatomical entity | 1 | 2 |
GO:0016020 | membrane | 2 | 1 |
Related structures:
AlphaFold database: A0A3Q8IA78
Term | Name | Level | Count |
---|---|---|---|
GO:0006807 | nitrogen compound metabolic process | 2 | 1 |
GO:0008152 | metabolic process | 1 | 1 |
GO:0018126 | protein hydroxylation | 5 | 1 |
GO:0018193 | peptidyl-amino acid modification | 5 | 1 |
GO:0018208 | peptidyl-proline modification | 6 | 1 |
GO:0018401 | peptidyl-proline hydroxylation to 4-hydroxy-L-proline | 7 | 1 |
GO:0019511 | peptidyl-proline hydroxylation | 6 | 1 |
GO:0019538 | protein metabolic process | 3 | 1 |
GO:0036211 | protein modification process | 4 | 1 |
GO:0043170 | macromolecule metabolic process | 3 | 1 |
GO:0043412 | macromolecule modification | 4 | 1 |
GO:0044238 | primary metabolic process | 2 | 1 |
GO:0071704 | organic substance metabolic process | 2 | 1 |
GO:1901564 | organonitrogen compound metabolic process | 3 | 1 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003824 | catalytic activity | 1 | 12 |
GO:0005488 | binding | 1 | 12 |
GO:0005506 | iron ion binding | 6 | 12 |
GO:0016491 | oxidoreductase activity | 2 | 12 |
GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 3 | 12 |
GO:0019842 | vitamin binding | 3 | 12 |
GO:0030246 | carbohydrate binding | 2 | 12 |
GO:0031406 | carboxylic acid binding | 4 | 12 |
GO:0031418 | L-ascorbic acid binding | 3 | 12 |
GO:0036094 | small molecule binding | 2 | 12 |
GO:0043167 | ion binding | 2 | 12 |
GO:0043168 | anion binding | 3 | 12 |
GO:0043169 | cation binding | 3 | 12 |
GO:0043177 | organic acid binding | 3 | 12 |
GO:0046872 | metal ion binding | 4 | 12 |
GO:0046914 | transition metal ion binding | 5 | 12 |
GO:0048029 | monosaccharide binding | 3 | 12 |
GO:0051213 | dioxygenase activity | 3 | 12 |
GO:0097159 | organic cyclic compound binding | 2 | 12 |
GO:1901363 | heterocyclic compound binding | 2 | 12 |
GO:0004656 | procollagen-proline 4-dioxygenase activity | 5 | 1 |
GO:0016706 | 2-oxoglutarate-dependent dioxygenase activity | 4 | 1 |
GO:0019798 | procollagen-proline dioxygenase activity | 4 | 1 |
GO:0031543 | peptidyl-proline dioxygenase activity | 3 | 1 |
GO:0031545 | peptidyl-proline 4-dioxygenase activity | 4 | 1 |
GO:0140096 | catalytic activity, acting on a protein | 2 | 1 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 289 | 293 | PF00656 | 0.531 |
CLV_C14_Caspase3-7 | 36 | 40 | PF00656 | 0.537 |
CLV_NRD_NRD_1 | 303 | 305 | PF00675 | 0.357 |
DEG_APCC_KENBOX_2 | 211 | 215 | PF00400 | 0.287 |
DEG_Nend_Nbox_1 | 1 | 3 | PF02207 | 0.559 |
DOC_CKS1_1 | 29 | 34 | PF01111 | 0.477 |
DOC_MAPK_HePTP_8 | 175 | 187 | PF00069 | 0.280 |
DOC_MAPK_MEF2A_6 | 178 | 187 | PF00069 | 0.280 |
DOC_PP4_FxxP_1 | 29 | 32 | PF00568 | 0.470 |
DOC_USP7_MATH_1 | 33 | 37 | PF00917 | 0.341 |
DOC_WW_Pin1_4 | 262 | 267 | PF00397 | 0.475 |
DOC_WW_Pin1_4 | 28 | 33 | PF00397 | 0.510 |
LIG_14-3-3_CanoR_1 | 115 | 120 | PF00244 | 0.492 |
LIG_14-3-3_CanoR_1 | 178 | 184 | PF00244 | 0.280 |
LIG_14-3-3_CanoR_1 | 217 | 227 | PF00244 | 0.365 |
LIG_APCC_ABBA_1 | 163 | 168 | PF00400 | 0.280 |
LIG_BIR_III_4 | 78 | 82 | PF00653 | 0.501 |
LIG_BRCT_BRCA1_1 | 232 | 236 | PF00533 | 0.292 |
LIG_CSL_BTD_1 | 142 | 145 | PF09270 | 0.364 |
LIG_FHA_1 | 180 | 186 | PF00498 | 0.290 |
LIG_FHA_1 | 219 | 225 | PF00498 | 0.477 |
LIG_FHA_1 | 263 | 269 | PF00498 | 0.483 |
LIG_FHA_1 | 67 | 73 | PF00498 | 0.434 |
LIG_FHA_2 | 169 | 175 | PF00498 | 0.295 |
LIG_FHA_2 | 50 | 56 | PF00498 | 0.469 |
LIG_LIR_Apic_2 | 27 | 32 | PF02991 | 0.485 |
LIG_LIR_Gen_1 | 179 | 187 | PF02991 | 0.280 |
LIG_LIR_Gen_1 | 20 | 30 | PF02991 | 0.357 |
LIG_LIR_Gen_1 | 3 | 8 | PF02991 | 0.467 |
LIG_LIR_Nem_3 | 177 | 183 | PF02991 | 0.285 |
LIG_LIR_Nem_3 | 20 | 26 | PF02991 | 0.340 |
LIG_LIR_Nem_3 | 233 | 239 | PF02991 | 0.320 |
LIG_LIR_Nem_3 | 3 | 7 | PF02991 | 0.475 |
LIG_LIR_Nem_3 | 99 | 105 | PF02991 | 0.353 |
LIG_REV1ctd_RIR_1 | 132 | 141 | PF16727 | 0.313 |
LIG_SH2_CRK | 181 | 185 | PF00017 | 0.295 |
LIG_SH2_CRK | 239 | 243 | PF00017 | 0.339 |
LIG_SH2_CRK | 4 | 8 | PF00017 | 0.484 |
LIG_SH2_GRB2like | 186 | 189 | PF00017 | 0.275 |
LIG_SH2_GRB2like | 238 | 241 | PF00017 | 0.313 |
LIG_SH2_NCK_1 | 110 | 114 | PF00017 | 0.475 |
LIG_SH2_SRC | 281 | 284 | PF00017 | 0.447 |
LIG_SH2_STAP1 | 110 | 114 | PF00017 | 0.367 |
LIG_SH2_STAP1 | 181 | 185 | PF00017 | 0.295 |
LIG_SH2_STAP1 | 68 | 72 | PF00017 | 0.432 |
LIG_SH2_STAT5 | 181 | 184 | PF00017 | 0.291 |
LIG_SH2_STAT5 | 186 | 189 | PF00017 | 0.254 |
LIG_SH2_STAT5 | 208 | 211 | PF00017 | 0.346 |
LIG_SH2_STAT5 | 254 | 257 | PF00017 | 0.273 |
LIG_SH2_STAT5 | 68 | 71 | PF00017 | 0.369 |
LIG_SUMO_SIM_par_1 | 170 | 177 | PF11976 | 0.279 |
LIG_SUMO_SIM_par_1 | 33 | 39 | PF11976 | 0.571 |
LIG_TRAF2_1 | 280 | 283 | PF00917 | 0.374 |
LIG_TRAF2_1 | 52 | 55 | PF00917 | 0.409 |
MOD_CK1_1 | 179 | 185 | PF00069 | 0.295 |
MOD_CK2_1 | 49 | 55 | PF00069 | 0.346 |
MOD_GlcNHglycan | 105 | 108 | PF01048 | 0.230 |
MOD_GlcNHglycan | 232 | 235 | PF01048 | 0.328 |
MOD_GlcNHglycan | 86 | 89 | PF01048 | 0.535 |
MOD_GSK3_1 | 24 | 31 | PF00069 | 0.471 |
MOD_N-GLC_1 | 218 | 223 | PF02516 | 0.313 |
MOD_N-GLC_2 | 188 | 190 | PF02516 | 0.290 |
MOD_NEK2_1 | 139 | 144 | PF00069 | 0.421 |
MOD_NEK2_1 | 286 | 291 | PF00069 | 0.526 |
MOD_NEK2_2 | 309 | 314 | PF00069 | 0.352 |
MOD_PIKK_1 | 218 | 224 | PF00454 | 0.376 |
MOD_PKA_1 | 230 | 236 | PF00069 | 0.374 |
MOD_PKA_1 | 304 | 310 | PF00069 | 0.373 |
MOD_PKB_1 | 302 | 310 | PF00069 | 0.397 |
MOD_Plk_2-3 | 168 | 174 | PF00069 | 0.295 |
MOD_Plk_4 | 139 | 145 | PF00069 | 0.369 |
MOD_Plk_4 | 168 | 174 | PF00069 | 0.295 |
MOD_Plk_4 | 179 | 185 | PF00069 | 0.295 |
MOD_Plk_4 | 193 | 199 | PF00069 | 0.320 |
MOD_Plk_4 | 309 | 315 | PF00069 | 0.439 |
MOD_Plk_4 | 66 | 72 | PF00069 | 0.351 |
MOD_ProDKin_1 | 262 | 268 | PF00069 | 0.475 |
MOD_ProDKin_1 | 28 | 34 | PF00069 | 0.513 |
MOD_SUMO_rev_2 | 271 | 278 | PF00179 | 0.381 |
MOD_SUMO_rev_2 | 36 | 42 | PF00179 | 0.421 |
TRG_DiLeu_BaEn_1 | 55 | 60 | PF01217 | 0.413 |
TRG_ENDOCYTIC_2 | 110 | 113 | PF00928 | 0.457 |
TRG_ENDOCYTIC_2 | 181 | 184 | PF00928 | 0.295 |
TRG_ENDOCYTIC_2 | 238 | 241 | PF00928 | 0.315 |
TRG_ENDOCYTIC_2 | 4 | 7 | PF00928 | 0.493 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1PCX6 | Leptomonas seymouri | 79% | 100% |
A0A0S4JJ67 | Bodo saltans | 41% | 90% |
A0A1X0NZK5 | Trypanosomatidae | 59% | 100% |
A0A3R7K694 | Trypanosoma rangeli | 57% | 100% |
A4H8D1 | Leishmania braziliensis | 83% | 100% |
A4HWQ3 | Leishmania infantum | 100% | 100% |
C9ZPS8 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 57% | 100% |
E9AQG0 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 95% | 100% |
Q4QF16 | Leishmania major | 97% | 100% |
V5D783 | Trypanosoma cruzi | 57% | 83% |